"Cilastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, IMIPENEM, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4.
| Descriptor ID |
D015377
|
| MeSH Number(s) |
D02.455.426.392.368.533.200 D10.251.355.325.200
|
| Concept/Terms |
MK 0791- MK 0791
- MK-791
- MK 791
- MK791
- MK0791
Cilastatin Sodium- Cilastatin Sodium
- Sodium, Cilastatin
- Cilastatin Monosodium Salt
- Monosodium Salt, Cilastatin
- Salt, Cilastatin Monosodium
|
Below are MeSH descriptors whose meaning is more general than "Cilastatin".
Below are MeSH descriptors whose meaning is more specific than "Cilastatin".
This graph shows the total number of publications written about "Cilastatin" by people in this website by year, and whether "Cilastatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cilastatin" by people in Profiles.
-
Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints. Surg Infect (Larchmt). 2012 Feb; 13(1):43-9.
-
Appropriate use of the carbapenems. S Afr Med J. 2004 Oct; 94(10 Pt 2):857-61.
-
An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia. Int J Antimicrob Agents. 2001 Mar; 17(3):177-88.